Specialtypharmajournal - specialtypharmajournal.com - Specialty Pharma Journal
General Information:
Latest News:
Grifols and Wake Forest-Based Charity Give Children with Hemophilia A Summer Camp Experience 23 Aug 2013 | 12:15 am
Research Triangle Park, N.C. – Aug. 22, 2013 – Grifols, a global healthcare company and leading producer of plasma medicines with North Carolina offices and operations in RTP and Clayton, is working w...
Alnylam's Hemophilia B Drug Receives Orphan Drug Designation 19 Aug 2013 | 08:49 pm
Alnylam Pharmaceuticals, Inc recently announced that its ALN-AT3 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for treatment of hemophilia B. ALN-AT3 is an RNA...
EMA Approves SmPC Change to Baxter's Advate 23 Jul 2013 | 12:57 am
Today, Baxter International Inc. announced that the European Medicines Agency (EMA) has authorized an updated to the Summary of Product Characteristics (SmPC) for its Advate to include findings of the...
Novo Nordisk Presents Findings from the Hemophilia Experiences, Results, and Opportunities Study 5 Jul 2013 | 08:08 pm
Novo Nordisk recently announced findings from the Hemophilia Experiences, Results, and Opportunities (HERO) study, which showed that bleed frequency and treatment regimen choice affected the use of he...
Baxter Presents Positive Data Supporting its Hemophilia A Treatment 3 Jul 2013 | 09:01 pm
Baxter International Inc. recently presented two comprehensive analyses supporting clinical and real-world results of its hemophilia A treatment. The company presented two studies of the Advate profi...
Biogen and Sobi Present New Findings from a Late-Stage Study of their Hemophilia B Candidate 2 Jul 2013 | 10:45 pm
Today, Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) presented new findings from their hemophilia B candidate at the XXIV International Society on Thrombosis and Hemostasis (ISTH) Congress. The ...
Baxter's Rixubis Receives FDA Approval for Prophylactic Treatment of Adults with Hemophilia B 27 Jun 2013 | 07:58 pm
The US Food and Drug Administration (FDA) approved Baxter International Inc.’s Rixubis [Coagulation Faxtor IX (Recombinant)] for routine prophylactic treatment, control of bleeding episodes, and perio...
CSL Behring Doses First Patient in Part 3 of its Pivotal Study for its Hemophilia A Treatment 6 Jun 2013 | 12:10 am
CSL Behring recently announced that it has dosed the first patient in Part 3 of its global Phase I/III study of its investigational treatment of hemophilia A. According to the company, the patient wa...
FDA Grants Orphan Drug Designation to Apgenix's Apocept for Myelodysplastic Syndromes 7 Feb 2013 | 09:16 pm
HEIDELBERG, Germany, Feb. 7, 2013 /PRNewswire/ -- Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases,...
New Common Application for HIV/AIDS Medicines Available Through Johnson & Johnson Patient Assistance Foundation, Inc. 12 Sep 2012 | 10:42 pm
NEW BRUNSWICK, N.J., Sept. 12, 2012 - The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) today announced that it has started to use a new common patient assistance program application f...
